Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial

OBJECTIVE This study examined the individual and combined effect of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), interleukin-6 (IL-6), and hs-CRP on the prediction of heart failure incidence or progression in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS A nested case-cohort study was conducted in 3,098 participants with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. RESULTS A higher value of each biomarker was significantly associated with a higher risk of heart failure incidence or progression, after adjustment for major risk factors. The hazard ratios per 1-SD increase were 3.06 (95% CI 2.37, 3.96) for NT-proBNP, 1.50 (1.27, 1.77) for hs-cTnT, 1.48 (1.27, 1.72) for IL-6, and 1.32 (1.12, 1.55) for hs-CRP. The addition of NT-proBNP to the model including conventional risk factors meaningfully improved 5-year risk-predictive performance (C statistic 0.8162 to 0.8800; continuous net reclassification improvement [NRI] 73.1%; categorical NRI [<5%, 5–10%, >10% 5-year risk] 24.2%). In contrast, the addition of hs-cTnT, IL-6, or hs-CRP did not improve the prediction metrics consistently in combination or when added to NT-proBNP. CONCLUSIONS Only NT-proBNP strongly and consistently improved the prediction of heart failure in patients with type 2 diabetes beyond a wide range of clinical risk factors and biomarkers.

[1]  B. Howard,et al.  Markers of Inflammation, Metabolic Risk Factors, and Incident Heart Failure in American Indians: The Strong Heart Study , 2012, Journal of clinical hypertension.

[2]  M. Woodward,et al.  Do Cardiac Biomarkers NT-proBNP and hsTnT Predict Microvascular Events in Patients With Type 2 Diabetes? Results From the ADVANCE Trial , 2014, Diabetes Care.

[3]  J. Chalmers,et al.  Importance of Blood Pressure Lowering in Type 2 Diabetes: Focus on ADVANCE , 2010, Journal of cardiovascular pharmacology.

[4]  Mark Woodward,et al.  Epidemiology: Study Design and Data Analysis , 1999 .

[5]  A. Maisel,et al.  Current and novel biomarkers in heart failure: bench to bedside , 2016, Current opinion in cardiology.

[6]  J. Stockman,et al.  A New Equation to Estimate Glomerular Filtration Rate , 2011 .

[7]  J. Danesh,et al.  C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.

[8]  J. McMurray,et al.  SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? , 2016, Diabetologia.

[9]  M. Pfeffer,et al.  Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. , 2014, The lancet. Diabetes & endocrinology.

[10]  V. Gudnason,et al.  N-terminal pro-brain natriuretic Peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. , 2011, Journal of the American College of Cardiology.

[11]  C. Yancy,et al.  Population Risk Prediction Models for Incident Heart Failure: A Systematic Review , 2015, Circulation. Heart failure.

[12]  Vilmundur Gudnason,et al.  Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review , 2008, PLoS medicine.

[13]  R. Newson.  Comparing the predictive power of survival models using Harrell ’ s c or , 2010 .

[14]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[15]  Mark Woodward,et al.  The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[16]  V. Gudnason,et al.  N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS , 2012, European heart journal.

[17]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[18]  O. Pedersen,et al.  Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria , 2004, Diabetologia.

[19]  Deepak L. Bhatt,et al.  Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial , 2014, Circulation.

[20]  R. Collins,et al.  Study rationale and design of ADVANCE: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation , 2001 .

[21]  M. Woodward,et al.  Circulating Inflammatory Markers and the Risk of Vascular Complications and Mortality in People With Type 2 Diabetes and Cardiovascular Disease or Risk Factors: The ADVANCE Study , 2014, Diabetes.

[22]  D. Levy,et al.  Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study , 2012, Circulation.

[23]  Advance Management Committee.  Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease – preterax and diamicron MR controlled evaluation , 2001, Diabetologia.

[24]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[25]  Spiros Denaxas,et al.  Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people , 2015, The Lancet.

[26]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[27]  Hollis G. Potter,et al.  Author Manuscript , 2013 .

[28]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[29]  S. Schinner.  Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .

[30]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[31]  B. Zinman,et al.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.

[32]  B. Gersh.  C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010 .

[33]  Roger Newson,et al.  Comparing the Predictive Powers of Survival Models Using Harrell's C or Somers’ D , 2010 .

[34]  Mark Woodward,et al.  Risk prediction in patients with heart failure: a systematic review and analysis. , 2014, JACC. Heart failure.

[35]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.